Australia - English - Department of Health (Therapeutic Goods Administration)

1 above australia pty ltd - dried magnesium sulfate, quantity: 388 mg (equivalent: magnesium, qty 60 mg); calcium carbonate, quantity: 109 mg (equivalent: calcium, qty 40 mg); sodium chloride, quantity: 76.26 mg (equivalent: sodium, qty 30 mg; equivalent: chloride, qty 46.26 mg); ascorbic acid, quantity: 45 mg; dl-alpha-tocopheryl acetate, quantity: 7.5 mg; nicotinamide, quantity: 8 mg; calcium pantothenate, quantity: 3.38 mg (equivalent: pantothenic acid, qty 2.73 mg); cyanocobalamin, quantity: 1.2 microgram; pyridoxine hydrochloride, quantity: 1.072 mg (equivalent: pyridoxine, qty 790 microgram); thiamine nitrate, quantity: 1.032 mg (equivalent: thiamine, qty 740 microgram); riboflavin sodium phosphate, quantity: 1.015 mg (equivalent: riboflavin, qty 650 microgram); pinus pinaster, quantity: 40 mg (equivalent: procyanidins (of pinus pinaster), qty 26 mg; equivalent: pinus pinaster, qty 40000 mg) - tablet, effervescent - excipient ingredients: citric acid; sorbitol; sodium bicarbonate; glucose monohydrate; sodium carbonate; potassium chloride; macrogol 6000; steviol glycosides; maltodextrin; silicon dioxide; modified food starch; mannitol; simethicone; flavour - antioxidant/reduce free radicals formed in the body ; enhance/promote energy levels ; maintain/support energy levels ; decrease/reduce/relieve symptoms of jet lag ; decrease/reduce/relieve symptoms of dehydration ; maintain/support body electrolyte balance

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - clenpiq is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. clenpiq is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute), which may result in accumulation of magnesium [see warnings and precautions (5.3)]. - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)]. - bowel perforation [see warnings and precautions (5.6)]. - toxic colitis or toxic megacolon. - gastric retention. - hypersensitivity to any of the ingredients in clenpiq [see adverse reactions (6.2)]. risk summary there are no data with clenpiq use in pregnant women to determine a drug-associated risk of adverse developmental outcomes. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1.2 times the recommended human dose based

Israel - English - Ministry of Health

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aventis pharma - glucose; citric acid anhydrous; sodium chloride; sodium bicarbonate; potassium chloride - effervescent tablet - 1.62gram ; 384mg ; 117mg ; 336mg ; 186mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

aventis pharma - glucose; citric acid anhydrous; sodium chloride; sodium bicarbonate; potassium chloride - effervescent tablet - 1.62gram ; 384mg ; 117mg ; 336mg ; 186mg

United States - English - NLM (National Library of Medicine)

salix pharmaceuticals, inc - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - plenvu® is indicated for cleansing of the colon in preparation for colonoscopy in adults. plenvu is contraindicated in the following conditions: risk summary there are no available data with plenvu in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with plenvu. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of plenvu in human milk, the effects on the breastfed child or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of plenvu to a child during lactation; therefore

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose, sodium chloride - solution for infusion - glucose 5 % (w/v) sodium chloride 0.45 % (w/v) - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 42.5 g/l; calcium chloride dihydrate, quantity: 0.184 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium chloride, quantity: 5.38 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, irrigation - excipient ingredients: water for injections - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 25 g/l; calcium chloride dihydrate, quantity: 0.184 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium chloride, quantity: 5.38 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, irrigation - excipient ingredients: water for injections - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 15 g/l; calcium chloride dihydrate, quantity: 0.184 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; sodium chloride, quantity: 5.38 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, irrigation - excipient ingredients: water for injections - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.